Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Myeloid Malignancies 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 37Cyclophosphamide 33Mycophenolic Acid 28Whole-Body Irradiation 24Cyclosporine 24Tacrolimus 22Radiotherapy 19Methotrexate 18Busulfan 18Antilymphocyte Serum 17Filgrastim 14Etoposide 14Vorinostat 11Bortezomib 11Bexarotene 11Methylprednisolone 10Lenalidomide 10pembrolizumab 9Rituximab 9Melphalan 9Gemcitabine 9Flow Cytometry 9Brentuximab Vedotin 9romidepsin 8mogamulizumab 8Methoxsalen 8fludarabine 7Magnetic Resonance Spectroscopy 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mycosis Fungoides × magrolimab × Clear all
NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡